Skip to main content

Table 1 Baseline characteristics of patients after propensity score matching

From: Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis

Variables Tofacitinib (n = 70) Abatacept (n = 70) P
Age, years 69.2 ± 10.1 68.6 ± 12.1 0.925
Female, n, % 59 (84.3) 58 (82.9) 1.000
Disease duration, years 14.8 ± 14.0 14.1 ± 13.0 0.678
Stage I/II/III/IV, % 20.0/10.0/32.9/37.1 25.7/12.9/32.9/28.6 0.694
Class 1/2/3/4, % 5.7/71.4/22.9/0.0 5.7/68.6/25.7/0.0 0.956
BMI, kg/m2 21.4 ± 3.3 21.8 ± 2.8 0.505
SE copy number 0/1/2, % 31.4/61.4/7.1 28.6/54.3/17.1 0.252
Current smoker, n (%) 4 (5.7) 5 (7.1) 1.000
Ever smoker, n (%) 14 (20.0) 21 (30.0) 0.241
No. of prior biologic use
 0 (biologic naïve ) 31 37 0.398
 1 13 14 0.830
 2 14 7 0.098
  ≥ 3 12 12 1.00
MTX use, n (%) 41 (58.6) 40 (57.1) 1.000
MTX dose, mg/week 8.4 ± 2.4 8.0 ± 2.7 0.441
Oral corticosteroid use, n (%) 27 (38.6) 24 (34.3) 0.726
Oral corticosteroid dose, mg/daya 4.5 ± 2.8 5.5 ± 3.9 0.288
MMP-3, ng/mL 243.6 ± 242.9 153.4 ± 134.6 0.140
SJC, 0–28 4.4 ± 4.1 3.7 ± 3.7 0.507
TJC, 0–28 5.9 ± 5.0 5.4 ± 5.3 0.557
ESR, mm/h 40.1 ± 32.0 38.2 ± 30.2 0.882
CRP, mg/dL 1.54 ± 1.92 1.48 ± 2.19 0.742
RF, U/mL 217.7 ± 529.9 165.1 ± 375.8 0.790
ACPA, U/mL 245 ± 393.3 256.6 ± 293.8 0.323
GH, VAS 0–100 mm 53.1 ± 28.4 52.2 ± 24.2 0.777
EGA, VAS 0–100 mm 47.8 ± 20.4 45.2 ± 15.8 0.522
SDAI 21.9 ± 12.1 20.3 ± 11.4 0.283
CDAI 20.3 ± 11.2 19.8 ± 10.0 0.326
DAS28-ESR 4.8 ± 1.4 4.7 ± 1.3 0.508
HAQ-DI 1.12 ± 0.81 1.07 ± 0.76 0.689
  1. aPrednisolone equivalents
  2. Results are expressed as means ± SD unless otherwise stated
  3. Comparisons of matched groups were performed using the Student’s t test for continuous variables and Pearson’s χ2 test for categorized variables. ACPA anticitrullinated peptide antibody, BMI body mass index, CRP C-reactive protein, CDAI Clinical Disease Activity Index, DAS28-ESR Disease Activity Score in 28 joints using the erythrocyte sedimentation rate, EGA evaluator global assessment of disease activity, ESR erythrocyte sedimentation rate, GH patient’s global assessment of general health, HAQ-DI Health Assessment Questionnaire Disability Index, MMP-3, matrix metalloproteinase 3, MTX methotrexate, RF rheumatoid factor, SE shared epitope, SDAI Simplified Disease Activity Index, SJC swollen joint count, TJC tender joint count